Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445111 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL30816909 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL310574 | 0.87 | VCAM1 (0.58) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL2156946 | 0.87 | ALDH1A1 (0.63) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL3824914 | 0.87 | ALDH1A1 (0.63) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL27650719 | 0.86 | ALDH1A1 (0.60) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL4641784 | 0.86 | ALDH1A1 (0.60) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL4337680 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL176357 | 0.85 | TTR (0.68) | ALDH1A1MAPTCYP3A4TSHRTDP1 | |
| SCHEMBL30825381 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MAPTCYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678450-B | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2023-06-20 | — | — | CN | disclosed |
| CN-109400625-B | Fused bicyclic compound and application thereof in medicine | 广东东阳光药业有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2019034096-A1 | FUSED BICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-02-21 | — | — | WO | disclosed |
| US-9822065-B1 | Benzazepine dicarboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046170-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046171-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-5844110-A | Synthetic triple helix-forming compound precursors | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1997037999-A1 | SYNTHETIC TRIPLE HELIX-FORMING COMPOUNDS | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1996023777-A1 | SYNTHETIC TRIPLE HELIX-FORMING COMPOUNDS | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1996-08-08 | — | — | WO | disclosed |
| US-5424479-A | Reacting aromatic hydroxycarboxylic acids in a mixture with methoxycarboxylic acids with dimethyl sulfate in water | CASSELLA AG (DE) | 1995-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | OPRM1, HIF1AN, MAOB | ALDH1A1 784/4885MAPT 986/4885CYP3A4 257/4885 |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | NOS1, NOS2, NOS3 | ALDH1A1 449/4885MAPT 1559/4885CYP3A4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.